• ホーム
  • 検索結果
  • Involvement of small ArfGAP1 (SMAP1), a novel Arf6-specific GTPase-activating protein, in microsatellite instability oncogenesis.

Involvement of small ArfGAP1 (SMAP1), a novel Arf6-specific GTPase-activating protein, in microsatellite instability oncogenesis.

Oncogene (2013-06-12)
F Sangar, A-S Schreurs, C Umaña-Diaz, A Clapéron, C Desbois-Mouthon, C Calmel, O Mauger, A Zaanan, C Miquel, J-F Fléjou, F Praz
要旨

Small ArfGAP1 (stromal membrane-associated protein 1, SMAP1), a GTPase-activating protein specific for ADP-ribosylation factor 6 (Arf6), which is a small GTPase acting on membrane trafficking and actin remodeling, is frequently mutated in various tumors displaying microsatellite instability (MSI), notably in MSI colorectal cancers (CRC). Genotyping of 93 MSI CRCs (40 stage II, 32 stage III and 21 stage IV) allowed us to underscore that SMAP1 mutation frequency was inversely correlated with disease stage (P=0.01). Analysis of 46 cancer cell lines showed that SMAP1 mutations occurred only in MSI tumors, and consisted exclusively in short insertion or deletion in the coding 10-adenine repeat, generating a premature termination codon located downstream the ArfGAP domain. SMAP1 transcript levels were significant decreased (P=0.006), and truncated SMAP1 protein could not be detected in cells displaying biallelic SMAP1 mutations, owing to its sensitivity to proteasome degradation. To investigate the role of SMAP1 mutations, we used the SMAP1-null HCT116 cell line and we established three isogenic SMAP1-complemented clones. Cell proliferation was first assessed in vivo using subcutaneous xenografts into immunodeficient mice. Tumors developed in all animals regardless of the cell line injected, but tumor volumes were significantly smaller for both SMAP1-complemented clones compared with HCT116 (P<0.0001, at the time of killing). In vitro, SMAP1 mutations also increased cell clonogenicity (P=0.02-0.04), cell proliferation (P=0.008) by shortening the G2/M phase and decreased cell invasiveness (P=0.03-0.003). In keeping, SMAP1-complemented HCT116 gained several mesenchymal markers (Snail, Slug and vimentin) considered as a hallmark of epithelial-to-mesenchymal transition. These observations are reminiscent of some clinical characteristics of MSI CRCs, notably their larger size and lower rate of metastasis. Our observations suggest that SMAP1 loss-of-function mutations in MSI CRC may contribute to the emerging oncogenic pathway involving abnormal Arf6 regulation.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
ビス-トリス, ≥98.0% (titration)
Sigma-Aldrich
抗GAPDH抗体、マウスモノクローナル, clone GAPDH-71.1, purified from hybridoma cell culture
SAFC
ビス-トリス
Sigma-Aldrich
Z-Leu-Leu-Leu-al, ≥90% (HPLC)
Sigma-Aldrich
ビス-トリス, BioXtra, ≥98.0% (titration)
Sigma-Aldrich
ビス-トリス, BioUltra, ≥99.0% (NT)
Sigma-Aldrich
ビス-トリス, BioPerformance Certified, suitable for cell culture, suitable for insect cell culture, ≥98.0%
Sigma-Aldrich
抗β-カテニン ウサギ宿主抗体, whole antiserum
Sigma-Aldrich
Anti-p53 antibody, Mouse monoclonal, clone DO-1, purified from hybridoma cell culture
Sigma-Aldrich
抗GAPDH抗体 マウス宿主抗体, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
モノクロナール抗Cdh1, clone DCS-266, purified from hybridoma cell culture
Sigma-Aldrich
抗UNC45A ウサギ宿主抗体, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAFC
ビス-トリス
Sigma-Aldrich
Monoclonal Anti-CDH1 antibody produced in mouse, clone 67A4, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
Anti-TP53 antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
Anti-SMAP1 antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
Anti-SMAP1 antibody produced in rabbit, affinity isolated antibody
Sigma-Aldrich
Anti-SMAP1 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
Sigma-Aldrich
Monoclonal Anti-CDH1 antibody produced in mouse, clone 3F4, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
Monoclonal Anti-TP53 antibody produced in mouse, clone 2C3, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
モノクロナール抗GAPDH マウス宿主抗体, clone 3C2, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
Anti-p53 antibody, Mouse monoclonal, clone DO-2, purified from hybridoma cell culture
Sigma-Aldrich
モノクロナール抗p53 マウス宿主抗体, clone DO-7, purified from hybridoma cell culture
Sigma-Aldrich
モノクロナール抗p53 マウス宿主抗体, clone PAb1801, purified from hybridoma cell culture
Sigma-Aldrich
モノクロナール抗p53 マウス宿主抗体, clone BP53-12, ascites fluid
Sigma-Aldrich
Monoclonal Anti-CDH1 antibody produced in mouse, Prestige Antibodies® Powered by Atlas Antibodies, clone CL1170, purified immunoglobulin, buffered aqueous glycerol solution
Sigma-Aldrich
Monoclonal Anti-CDH1 antibody produced in mouse, Prestige Antibodies® Powered by Atlas Antibodies, clone CL1172, purified immunoglobulin, buffered aqueous glycerol solution
Sigma-Aldrich
Monoclonal Anti-CDH1 antibody produced in mouse, Prestige Antibodies® Powered by Atlas Antibodies, clone CL1180, purified immunoglobulin, buffered aqueous glycerol solution
Sigma-Aldrich
Monoclonal Anti-p53 antibody produced in mouse, Prestige Antibodies® Powered by Atlas Antibodies, clone CL2199, purified immunoglobulin, buffered aqueous glycerol solution

ソーシャルメディア

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

研究、開発、製造

私たちは、バイオテクノロジーと医薬品の研究&開発および製造のソリューションとサービスを提供する、グローバルなライフサイエンス業界のリーディングサプライヤーです。

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates.All Rights Reserved.

当ウェブサイトのいかなる内容についても、許可なく複写することを禁じます。